Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Evaluation of the safety and efficacy of m-beam and m-beac due to the shortage supply of melphalan
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-HPS-096
- By: MIYAGAWA, Keiko (Kameda Medical Center)
- Co-author(s): Keiko Miyagawa: Pharmacy, Kameda Medical Center, Kamogawa, Japan
Yusuke Nakagawa: Pharmacy, Kameda Medical Center, Kamogawa, Japan
Tatsuya Isezaki: Pharmacy, Kameda Medical Center, Kamogawa, Japan
Koji Masuda
Osamu Yasumuro: Pharmacy, Kameda Medical Center, Kamogawa, Japan
Ryohkan Funakoshi: Pharmacy, Kameda Medical Center, Kamogawa, Japan
Kosei Matsue: Hematology, Kameda Medical Center, Kamogawa, Japan - Abstract:
Background
Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023